Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: quizartinib dihydrochloride, ningetinib, cep-2563 +42 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 8,932 | 0.76 |
| pathways Reactome | 27 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 10301
Sealed predictions
- FLT3 in dopamine neurons, braak-0.05 (p 0.891) → -0.08 (p 0.842)receipt 10308
Swarm cases
receipt 10308: FLT3 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.935, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.976, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.956, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.10, sign flips 5; without severely affected donors -0.02 (p 0.935, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FLT3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts